Press Release

Contract

by Shire Ltd
August 18th, 2006
  Exhibit 99.03
Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
   
Press Release  
   

18 August 2006

Shire plc (the "Company")

The Company announces that on 17 August 2006 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire plc Portfolio Share Plan (the “Plan”).

Awards of Stock Settled Appreciation Rights (“SARs”) under Part A of the Plan

Name of PDMR Type of Security No of Ordinary
Shares or ADRs
Exercise price
Matthew Emmens
(Executive Director)*
American Depositary
Receipt (“ADR”)
126,831  $49.36
Angus Russell
(Executive Director)*
Ordinary Share 128,542  £8.645
Michael Cola ADR   15,000  $49.36
David Pendergast ADR   14,000  $49.36
Tatjana May Ordinary Share   34,000  £8.645
Barbara Deptula ADR   13,334  $49.36
Eliseo Salinas ADR   10,667  $49.36
Joseph Rus ADR   11,667  $49.36
John Lee ADR    8,667  $49.36
Anita Graham ADR    8,667  $49.36

     *Awards to Executive Directors are subject to performance targets

SARs will normally vest after three years. subject to any performance targets. Once vested, SARs will be capable of exercise for a period of two years. No consideration was paid for the grant of the SARs.

Performance Share Awards (“PSP Awards”) under Part B of the Plan

Name of PDMR Type of Security No of Ordinary
Shares or ADRs
Market
value
Matthew Emmens
(Executive
Director)*
American Depositary
Receipt (“ADR”)
92,671  $49.36
Angus Russell
(Executive
Director)*
Ordinary Share 96,406  £8.645
Michael Cola ADR 14,000  $49.36
David Pendergast ADR 13,334  $49.36
Tatjana May Ordinary Share 34,000  £8.645
Barbara Deptula ADR 13,334  $49.36
Eliseo Salinas ADR 10,667  $49.36






Joseph Rus ADR 11,334 $49.36
John Lee ADR 8,667 $49.36
Anita Graham ADR 11,334 $49.36

     *Awards to Executive Directors are subject to performance targets

The PSP awards will normally vest after three years, subject to any performance targets. Once vested, sufficient ordinary shares or ADRs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of PSP awards.

T May

Company Secretary

For further information please contact:

Investor Relations Cléa Rosenfeld (Rest of the World)  +44 1256 894 160
Brian Piper (North America)  +1 484 595 8252


Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.